Idera Pharma (NASDAQ:IDRA) presented results of its Phase 1 trial of tilsotolimod as monotherapy in patients with various refractory solid tumors.
Tilsotolimod is a toll-like receptor 9 agonist that activates cancer-fighting T-cells to target solid tumors. Of the study’s 29 evaluable patients, stable disease (SD) was observed in 13 patients with a disease control rate of 45%. The duration of SD ranged from 1.3 to 9.7-plus months. Of the 13 patients with SD, five had maximum tumor shrinkage greater than 10% below baseline.
“It is highly encouraging to see the number and duration of stable diseases, including some with tumor reductions, from this study across a wide spectrum of difficult-to-treat refractory solid tumor types,” Hani Babiker, associate director of the Phase 1 program, said in a statement.
Tilsotolimod received FDA fast track designation in 2017 for the treatment of anti-PD-1 refractory melanoma in combination with ipilimumab, as well as FDA orphan drug designation for the treatment of later stages of melanoma.
